Achillion Pharmaceuticals (ACHN) reported quarterly earnings results on Tuesday, May-3-2016. The company said it had a profit of $-0.13 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.14. During the same quarter in the previous year, the company posted $-0.17 EPS.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Robert W. Baird Upgraded Achillion Pharmaceuticals on Feb 26, 2016 to ” Outperform”, Price Target of the shares are set at $10.Shares were Reiterated by Maxim Group on Feb 25, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $11 .
Achillion Pharmaceuticals opened for trading at $8.57 and hit $8.84 on the upside on Monday, eventually ending the session at $8.82, with a gain of 3.16% or 0.27 points. The heightened volatility saw the trading volume jump to 13,60,039 shares. Company has a market cap of $1,205 M.
In a different news, on Dec 30, 2015, Mary Kay Fenton (Chief Financial Officer) sold 43,500 shares at $10.08 per share price. According to the SEC, on Dec 30, 2015, David Apelian (Chief Medical Officer) sold 10,000 shares at $10.50 per share price. On Nov 12, 2015, Nicole Vitullo (director) sold 550,000 shares at $10.25 per share price, according to the Form-4 filing with the securities and exchange commission.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.